The AML patients with a higher WBC count had a significantly higher CRIP1 expression (p < 0.001), while the gene mutations, including TP53, RUNX1, and FLT3-ITD, had no significant correlation with CRIP1 expression (Supplementary Figure S3). This evidence concerns the gene FLT3 and acute myeloid leukemia.